STELLIUM 1: First-In-Man Follow-up Evaluation of Bioabsorbable Polymer-Coated Paclitaxel-Eluting Stent

被引:8
|
作者
Kozuki, Amane [1 ]
Shite, Junya [1 ]
Shinke, Toshiro [1 ]
Miyoshi, Naoki [1 ]
Sawada, Takahiro [1 ]
Hellig, Farrel [2 ]
Abelson, Mark [3 ]
Brown, Basil [4 ]
Khan, Sajidah [5 ]
Mpe, Martin [6 ]
Ntsekhe, Mpiko [7 ]
Conway, Damian [8 ]
Hirata, Ken-ichi [1 ]
机构
[1] Kobe Univ, Grad Sch Med, Div Cardiovasc Med, Dept Internal Med,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Sunward Pk Hosp, Johannesburg, South Africa
[3] Vergelegen Hosp, Somerset W, South Africa
[4] PE Prov Hosp, Port Elizabeth, South Africa
[5] Inkosi Albert Luthuli Hosp, Durban, South Africa
[6] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa
[7] First Mil Hosp, Pretoria, South Africa
[8] Disa Vasc Pty Ltd, Cape Town, South Africa
关键词
Bioabsorbable polymer; Neointima; Optical coherence tomography; Paclitaxel eluting stents; OPTICAL COHERENCE TOMOGRAPHY; CORONARY-ARTERY; SLOW-RELEASE; DOUBLE-BLIND; NEOINTIMAL COVERAGE; 6-MONTH; SAFETY; THROMBOSIS; LESIONS; TRIAL;
D O I
10.1253/circj.CJ-09-0859
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Durable polymers used for first-generation drug-eluting stents (DES) potentially contribute to persistent inflammation and late DES thrombosis. The vascular response to the Stellium (TM) stent, which is coated with an absorbable polymer for slow release of low-dose paclitaxel, was evaluated in the present study. Methods and Results: The 37 patients with stable angina were implanted with 47 Stellium (TM) stents. Quantitative coronary angiography (QCA) was performed at baseline, and QCA and optical coherence tomography (OCT) were performed at 6 months post-implant. The primary endpoint was major adverse cardiac events (MACE). At 6 months, 1 case of MACE occurred because of total occlusion of a protected left main artery. In-stent and segment binary restenosis rates were both 0%. In-stent late loss was 0.19 +/- 0.54 mm. Altogether, 5,564 struts were visualized by OCT and mean neointimal thickness was 150.03 +/- 146.36 mu m. The number of well-apposed struts with and without neointima overlay was 5,135 (92.29%) and 396 (7.12%), respectively. Pen-strut low intensity was observed in 518 struts (9.31%). Conclusions: This first-in-man study of the Stellium (TM) stent shows the promising possibility of bioabsorbable polymeric surface coating paclitaxel-eluting stents out to 6 months. The low rate of pen-strut low intensity suggests low cellular toxicity of the Stellium (TM) stent compared with the first-generation DES. (Circ J 2010; 74: 2089-2096)
引用
收藏
页码:2089 / 2096
页数:8
相关论文
共 50 条
  • [21] Comparison of efficacy between paclitaxel-eluting stents with different polymers in terms of major adverse cardiac events and stent thrombosis up to 12 months of clinical follow-up
    Suh, Soon Yong
    Lee, Kyoung Hoon
    Moon, Jeonggeun
    Kang, Woong Chol
    Han, Seung Hwan
    Ahn, Tae Hoon
    Shin, Eak Kyun
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 152 (03) : 392 - 395
  • [22] 5-Year Follow-Up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-Metal Stent in Acute ST-Segment Elevation Myocardial Infarction A Follow-Up Study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction With ST-Segment Elevation) Trial
    Vink, Maarten A.
    Dirksen, Maurits T.
    Suttorp, Maarten J.
    Tijssen, Jan G. P.
    van Etten, Jeroen
    Patterson, Mark S.
    Slagboom, Ton
    Kiemeneij, Ferdinand
    Laarman, Gerrit J.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (01) : 24 - 29
  • [23] Comparison of paclitaxel-eluting vs. everolimus-eluting stents implanted simultaneously in different lesions of the same coronary artery: 12-month follow-up with optical coherence tomography
    de la Torre Hernandez, Jose M.
    Lee, Dae-Hyun
    Garcia-Camarero, Tamara
    Sainz Laso, Fermin
    Zueco, Javier
    EUROINTERVENTION, 2013, 9 (08) : 952 - 958
  • [24] RAPSTROMTM First-in-Man Study Long-Term Results of a Biodegradable Polymer Sustained-Release Sirolimus-Eluting Stent in De Novo Coronary Stenoses
    Kumar, Prathap
    Pillai, Ramakrishna
    Sreedharan, Madhu
    Davidson, Deepak
    Manjunath, C. N.
    Fischer, Louie
    Balakrishnan, K. P.
    D'Ascenzo, Fabrizio
    Sheiban, Imad
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2014, 27 (04) : 373 - 380
  • [25] Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial sub-study
    Rusinaru, Dan
    Vrolix, Mathias
    Verheye, Stefan
    Chowdhary, Saqib
    Schoors, Danny
    Di Mario, Carlo
    Desmet, Walter
    Donohoe, Dennis J.
    Ormiston, John A.
    Knape, Charlene
    Bezerra, Hiram
    Lansky, Alexandra
    Wijns, William
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2015, 86 (07) : 1141 - 1150
  • [26] Clinical outcomes and predictors of restenosis in patients with femoropopliteal artery disease treated using polymer-coated paclitaxel-eluting stents or drug-coated balloons
    Yoshioka, Naoki
    Tokuda, Takahiro
    Koyama, Akio
    Yamada, Takehiro
    Nishikawa, Ryusuke
    Shimamura, Kiyotaka
    Takagi, Kensuke
    Morita, Yasuhiro
    Tanaka, Akihito
    Ishii, Hideki
    Morishima, Itsuro
    Murohara, Toyoaki
    HEART AND VESSELS, 2022, 37 (04) : 555 - 566
  • [27] Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry
    Zhang Rui-yan
    Zhang Qi
    Zhu Jin-zhou
    Chen Liang-long
    Zhang Chen-yun
    Zhou Xu-chen
    Yuan Yong
    Zhong Zhi-xiong
    Li Lang
    Qiu Jian
    Wang Wei
    Chen Xi-ming
    Yang Zhi-jian
    Yan Jin-chuan
    Chen Shao-liang
    Hou Yu-qing
    Wu Yan-qing
    Luo Hai-ming
    Qiu Jian-ping
    Zhu Li
    Wang Yan
    Fu Guo-sheng
    Wang Jian-an
    Ma Kang-hua
    Yin Yue-hui
    Zhang Dai-fu
    Hu Xue-song
    Zhu Guo-ying
    Shen Wei-feng
    CHINESE MEDICAL JOURNAL, 2011, 124 (21) : 3521 - 3526
  • [28] Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent The EVOLVE II Randomized Trial
    Kereiakes, Dean J.
    Meredith, Ian T.
    Windecker, Stephan
    Jobe, R. Lee
    Mehta, Shamir R.
    Sarembock, Ian J.
    Feldman, Robert L.
    Stein, Bernardo
    Dubois, Christophe
    Grady, Timothy
    Saito, Shigeru
    Kimura, Takeshi
    Christen, Thomas
    Allocco, Dominic J.
    Dawkins, Keith D.
    Circulation-Cardiovascular Interventions, 2015, 8 (04)
  • [29] Predictors of Stent Thrombosis after Everolimus-Eluting and Paclitaxel-Eluting Stents: The Pooled SPIRIT Randomized Trial Experience at Two Years of Follow-Up
    Kirtane, Ajay
    Sood, Poornima
    Applegate, Robert J.
    Yaqub, Manejeh
    Onuma, Yoshinobu
    Wang, John C.
    Su, Xiaolu
    Miquel-Hebert, Karine
    Lansky, Alexandra J.
    Kereiakes, Dean J.
    Simonton, Charles A.
    Sudhir, Krishnankutty
    Serruys, Patrick W.
    Stone, Gregg W.
    CIRCULATION, 2010, 122 (21)
  • [30] Long-term (≥2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results
    Tae-Hoon Kim
    Jung-Sun Kim
    Byoung-Keuk Kim
    Young-Guk Ko
    Donghoon Choi
    Yangsoo Jang
    Myeong-Ki Hong
    The International Journal of Cardiovascular Imaging, 2011, 27 : 875 - 881